http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-050631-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 |
| filingDate | 2005-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-050631-A1 |
| titleOfInvention | COMBINATION OF ORGANIC COMPOUNDS |
| abstract | Pharmaceutical composition, comprises a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of: i) compounds with increasing HDL; ii) antidiabetic drugs; iii) an antihypertensive agent; iv) a cholesterol absorption modulator; v) apo-A1 analogs and mimetics; vi) renin inhibitors; vii) thrombin inhibitors; viii) aldosterone inhibitors; ix) GLP-1 agonists; x) glucagon receptor antagonists; xi) cannabinoid receptor 1 agonists; xii) anti-obesity agents; and xiii) platelet aggregation inhibitors; or, in each case, a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for the treatment of additions (for example, nicotine and cocaine), dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, shock, intermittent claudication, restenosis after of PCTA, hypertension, obesity including CV risk reduction in obese patients, inflammation, arthritis, cancer including breast, colon and prostate cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, IBDs (irritable bowel disease ), Crohn's disease, hypofibrinolysis, hypercoagulable state, metabolic / cardiometabolic syndrome, elevated CRP, appearance of microalbuminuria, proteinuria reduction, renal failure (DM, non-DM), non-alcoholic liver fat NASH (non-alcoholic hepatitis) , CV events in patients with a high CRP, vascular dementia, pso riasis, reperfusion damage from ischemia, asthma, COPD, eosinophilia, RA, airway hypersensitivity (AHR), inflammatory digestive diseases (eg, ulcerative colitis), inflammatory response diseases induced by antigen. The compounds herein are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions such as impaired glucose tolerance, hyperglycemia, insulin resistance, type 1 and type 2 diabetes, and Syndrome X. Also contemplated is administration of the combinations of the present for the improvement of cardiac metabolism and cardioprotection in patients with heart transplantation, to facilitate the cessation or reduction of smoking and to prevent or treat conditions associated with smoking. Claim 4: The pharmaceutical composition according to claim 3, wherein the dual agonist / PPAR dual range is of the formula (1). Claim 5: The pharmaceutical composition according to claim 3, wherein the dual agonist / PPAR dual range is 3-isobutyl-8- (6-methoxy-isoquinolin-4-ylmethyl) -1-methyl-3,7-dihydro -purine-2,6-dione. |
| priorityDate | 2004-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 136.